Takara Bio announced that they have bought land in Kusatsu for a GMP-based manufacturing plant of drugs based on gene therapy, regenerative medicine and transgenic cells. Investment plans cover about 7 billion Yen, covered by own capital.

Takara Bio news release, August 9, 2012